Carbonic anhydrase 9 expression is associated with poor prognosis, tumor proliferation, and radiosensitivity of thymic carcinomas

Yoichi Ohtaki1,2,3, Kimihiro Shimizu1,2, Reika Kawabata-Iwakawa4, Navchaa Gombodorj1, Bolag Altan5, Susumu Rokudai4, Arito Yamane4, Kyoichi Kaira5, Takehiko Yokobori5, Toshiteru Nagashima1,2, Kai Obayashi1,2, Seshiru Nakazawa1,2, Misaki Iijima1,2, Takayuki Kosaka1,2, Toshiki Yajima1,2, Akira Mogi1,2, Hiroyuki Kuwano2, Ken Shirabe2 and Masahiko Nishiyama3,4

1Division of General Thoracic Surgery, Integrative Center of General Surgery, Gunma University Hospital, Maebashi, Gunma, Japan
2Department of General Surgical Science, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan
3Education and Research Support Center, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan
4Department of Molecular Pharmacology and Oncology, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan
5Department of Oncology Clinical Development, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan
6Department of Innovative Cancer Immunotherapy, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan

Correspondence to: Kimihiro Shimizu, email: kmshimizu@gmail.com

Keywords: thymic epithelial tumor; thymoma; thymic carcinoma; CA9; hypoxia

Received: May 25, 2018  Accepted: January 22, 2019  Published: February 12, 2019

ABSTRACT

Introduction: Thymic epithelial tumors (TETs) comprise several histologies of thymoma and thymic carcinomas (TCs), and TC frequently metastasizes and causes death. We therefore aimed here to identify key molecules closely related to prognosis and their biological roles in high-risk TETs, particularly TCs.

Results: RNA sequence analysis demonstrated that hypoxia-related genes were highly expressed in TETs. The expression of the hypoxia-related gene CA9 was noteworthy, particularly in TCs. Immunohistochemical analysis revealed that CA9 was expressed in 81.0% of TCs and 20.7% of all TET samples. CA9 expression was significantly associated with Masaoka stage, WHO classification, and recurrence-free survival after tumor resection (P = 0.005). The down-regulation of CA9 transcription in TC cell lines by small interfering RNAs significantly inhibited CA9 expression, which inhibited proliferation and increased sensitivity to irradiation.

Conclusions: CA9 expression may serve as a significant prognostic marker of TETs and therefore represents a potential target for the development of novel drugs and radiation-sensitizing therapy designed to improve the outcomes of patients with TCs.

Materials and Methods: We performed comprehensive transcriptome sequencing of 23 TETs and physiologic thymic specimens to identify genes highly and specifically expressed in high-risk TETs, particularly TCs. We performed immunohistochemical analysis of 179 consecutive surgically resected TETs to evaluate the significance of the association of protein expression with clinicopathological features and prognosis. The biological significance of the most promising prognostic marker was further studied using the TC cell lines, Ty-82 and MP57.
INTRODUCTION

Thymic epithelial tumors (TETs) are the most frequent neoplasms arising from the thymic epithelium in the anterior mediastinum. TETs represent a relatively rare tumor that accounts for 0.2%–1.5% of malignant tumors, and only 2,104 patients underwent surgery for TET in Japan in 2014 [1]. Besides tumor staging according to Masaoka [2], tumor histology is an important prognostic factor of TETs [3, 4]. TETs comprise several histologies of thymomas and thymic carcinomas (TCs) as follows: Patients with low-risk thymomas such as types A, AB and B1 have a better prognosis; high-risk thymomas occasionally recur as types B2 and B3; and patients frequently die because of TCs [3, 4]. The prognosis of patients with TETs, even in case of tumor recurrence, is significantly better compared to other tumor entities like lung cancer [5, 6]. However, while 10-year overall survival (OS) rates of all TET patients was reported as 84.7% [3], 5-year and 10-year OS rates of TC patients were reported as 60% and 40%, respectively, and cumulative incidence of recurrence rises up to 40% at 10 years [7].

Several molecularly-targeted therapies developed using gene expression studies and analysis of mutations include a KIT inhibitor, epidermal growth factor receptor tyrosine kinase inhibitors, a histone deacetylase inhibitor, and an anti-insulin like growth factor 1 receptor antibody [8–10]. However, these therapies have limited efficacy for treating patients with advanced TETs.

Next generation sequencing (NGS) technology has clarified in detail the frequency of gene alterations and gene expressions specific to diverse neoplasms, which has led to the development of new molecularly-targeted therapies. Several specific gene alterations occur on patients with TETs [11–13], and the TCGA study on TET showed that tumor mutational burden of TCs was higher than that of thymomas [14]. However, significantly mutated genes in TETs like GTF2I, HRAS, NRAS, and TP53 are not targetable [14]. Although comprehensive transcriptome sequence analysis is a potent tool to identify potential target genes, only limited data are available for TETs. Especially, hypoxia related-proteins are shown detected in association with the membranes of tumor thymus (Supplementary Figure 1). In contrast, CA9 was not detected in physiologic thymic specimens (Figure 1B), which suggested their importance in thymic carcinoma. Therefore, we chose CA9 among the top 20 candidates.

RESULTS

Comprehensive transcriptome sequence analysis of TETs

To determine differences in biological backgrounds, we compared the gene expression profiles acquired using NGS RNA-seq of 23 TETs and four physiologic thymic specimens (Figure 1A). Unsupervised hierarchical cluster analysis of 9,200 differentially expressed genes (DEGs) demonstrated that TCs exhibited a unique gene expression profile compared with those of physiologic thymic specimens and low-risk TETs. TCs and type B3 thymomas were classified into the same cluster, forming adjacent subclusters (Figure 1A).

We found that the expression levels of 158 genes in TCs were significantly increased compared with those in other types of thymomas and physiologic thymic specimens (log2 fold-change > 4, adjusted P < 0.05). As previously suggested [16, 17], metabolic or hypoxia-related genes such as GLUT1 and HIF1A were highly expressed in TCs (Figure 1B), which suggested their importance in TCs, and CA9 ranked among the top 20 highly expressed genes specific expressed in TCs (Table 1). CA9 is a well-known gene, and it could be a good therapeutic target for thymic carcinoma. Therefore, we chose CA9 among the top 20 candidates.

Immunohistochemical analysis and prognostic significance of CA9 expression

We next focused on the clinical significance of CA9 expression. CA9 was not detected in physiologic thymus (Supplementary Figure 1). In contrast, CA9 was detected in association with the membranes of tumor cells (Figure 2). When we tentatively classified the tumor samples into CA9-positive and -negative groups with a cutoff at staining intensity <20%, 20.7% (37/179) of all samples were CA9-positive. Figure 2 shows representative CA9-negative (A) and CA9-positive (B) TC samples. Positive CA9 expression significantly correlated with advanced Masaoka stage (III and IV) and WHO classification (TC). CA9 expression was undetectable in type A thymomas, and only 4/93 (4.3%) of low-risk thymoma expressed CA9, whereas 17/21 (81.0%) of TCs expressed CA9 (Table 2). Although the frequency of CA9 expression by high-risk thymoma, especially type B3 tumors, was higher compared with that of CA9 mRNA expression, the positivity of CA9 expression gradually increased according to histology, and CA9 expression data were generally consistent with its mRNA levels (Supplementary Figure 1B and 1C). We validated the mRNA values provided from NGS using RT-qPCR, and they correlated strongly with each other (Supplementary Figure 2).
Univariate analyses revealed that CA9 expression was a predictor of OS and RFS as well as the Masaoka Stage and WHO classifications (Table 3). Kaplan–Meier analysis did not indicate a statistically significant difference in OS ($P = 0.194$) between CA-positive and -negative patients with TETs, although the RFS ($P = 0.005$) of CA9-positive patients was significantly shorter compared with CA-negative patients (Figure 2C and 2D). The 5- and 10-year OS rates were 90.7% and 86.3%, respectively, of patients with CA9-negative TETs and 89.1% and 67.1%, respectively, for patients with CA9-positive TETs. In contrast, RFS of CA9-positive patients was significantly shorter compared with CA-negative patients (5-year RFS, 86.7% vs 69.4%; 10-year RFS, 80.3% vs 60.7%, respectively).

**Figure 1:** (A), Hierarchical Cluster Analysis of 9,200 genes differentially expressed by thymic epithelial tumors and physiologic thymic specimens. Thymic carcinoma (TC) formed a cluster distinct from thymomas. The TC subcluster was distinct but adjacent to a cluster of type B3 thymomas. (B), mRNA expression of hypoxia-related genes highly expressed in TCs. Among them, CA9 was expressed at the highest levels. "These samples were collected from recurrent tumors."
The role of CA9 in the proliferation and radiosensitivity of TC cells

CA9 expression is associated with hypoxia [18], which is consistent with our present findings that CA9 as well as HIF1a were induced in Ty-82 cells exposed to hypoxia, but not at normoxia (Figure 3A). Interestingly, cell proliferation, specifically under hypoxia, was significantly suppressed by the knockdown of CA9 expression by Ty-82 cells. CA9-specific siRNA1 and siRNA2 significantly inhibited the expression of CA9 mRNA and protein (Figure 3B and 3C) as well as the proliferation of Ty-82 cells (Figure 3D and 3E) under hypoxia but not normoxia. We validated the effect using another TC cell line, MP57. Both CA9 and HIF1a were induced in MP57 cells exposed to hypoxia, but not in normoxia and CA9-specific siRNAs significantly inhibited the CA9 protein expression only in hypoxia (Figure 3F). The proliferation of MP57 cells was inhibited under hypoxia but not normoxia (Figure 3G and 3H).

The induction of hypoxia-related factor causes cellular resistance to radiation [19]. We therefore studied the effect of CA9 on the radiosensitivity of TC cells. We found that reduced CA9 expression was significantly associated with reduced proliferation in response to irradiation under hypoxia in both Ty-82 and MP57 (Figure 4B and 4D). Although the similar combination effects of CA9 inhibition and radiation was observed in MP57 cells in normoxia (Figure 4C), the radiosensitivity of Ty-82 cells transfected with the siRNAs was not significantly altered under normoxia (Figure 4A).

DISCUSSION

Here we conducted comprehensive gene profiling revealing that DEGs expressed by high-risk TCs and type B3 thymomas form a cluster distinct from those of low-risk TETs and B2 thymoma. TC could be classified into an adjacent subcluster that was distinct from B3 thymomas. Certain hypoxia-related genes were specifically expressed at high levels by TCs. Among them, CA9 expression of TC showed more than a 50-fold increase compared with all other TETs and physiologic thymus. Analysis of a cohort of 179 TETs shows that CA9 was expressed at significantly elevated levels in TCs, which was closely associated with clinical stage and shorter RFS of patients with TETs.

An in vitro study using the TC cell lines, Ty-82 and MP57 show that reduction of CA9 expression inhibited TC cell proliferation specifically under hypoxia, and

Table 1: Highly expressed genes in thymic carcinoma compared with thymoma and normal thymus

| Gene names | log2 fold change | p-adj | log2 fold change | p-adj |
|------------|-----------------|-------|-----------------|-------|
| KIT        | 7.372451923     | 6.42289E-75 | 6.912628497     | 2.487E-159 |
| IGF2BP3    | 9.555242809     | 1.53211E-56 | 9.010418744     | 1.5625E-93 |
| MYBPC1     | 11.62244454     | 4.11339E-55 | 11.61111489     | 1.0085E-48 |
| LOC101929567 | 5.866046057   | 4.19853E-52 | 6.847485322     | 2.3498E-14 |
| GF11B      | 7.497300336     | 2.13154E-46 | 6.922503459     | 4.1378E-34 |
| TMEM151B   | 7.98577363      | 8.8341E-46  | 10.8168326      | 2.423E-30  |
| C12orf74   | 8.589187584     | 2.96825E-42 | 9.202491871     | 9.1126E-11 |
| ASCL4      | 5.917932051     | 6.23545E-42 | 9.500790766     | 1.7123E-11 |
| PLA2G3     | 7.705117681     | 2.19373E-40 | 5.834090367     | 6.4384E-13 |
| PLEKHG7    | 8.611314393     | 1.50784E-39 | 11.47286352     | 5.2238E-19 |
| CA9        | 5.870965549     | 6.28493E-38 | 6.026697828     | 8.6149E-18 |
| TLDC2      | 5.779065153     | 6.28493E-38 | 4.315569111     | 7.5577E-13 |
| MYEOV      | 6.750407404     | 2.87563E-37 | 9.457792251     | 2.4664E-39 |
| ALOX12B    | 7.734309926     | 6.93573E-37 | 11.52965971     | 1.396E-18  |
| KIAA1804   | 4.232409322     | 1.19054E-36 | 5.746459504     | 2.0636E-69 |
| MFSD2A     | 4.780735943     | 9.66369E-35 | 4.907613797     | 5.9426E-11 |
| ONECUT2    | 4.417990532     | 5.23634E-34 | 5.529165104     | 5.0619E-13 |
| DHR59      | 8.484637854     | 6.84171E-33 | 7.31756319      | 2.9162E-30 |
| HOXB13     | 10.40352536     | 8.03243E-33 | 9.234120918     | 1.1286E-10 |
| PPM1H      | 4.781155507     | 5.13178E-32 | 5.013480894     | 9.5487E-24 |
Figure 2: Immunohistochemical analysis of CA9 expression and the association of CA9 expression with overall survival (OS) and recurrence-free survival (RFS) of patients with thymic epithelial tumors. CA9-negative (A) and CA9-positive thymic carcinomas (B). When >20% of epithelial cells were stained, the tumor was tentatively defined as CA9-positive (+). Kaplan–Meier analysis of OS (C) and RFS (D). CA9 expression significantly associated with RFS but not with OS of patients with TETs.
increased irradiation sensitivity. These findings indicate that CA9 may play a key role in TC and may therefore serve as sensitive and specific marker of high-risk TET, as a novel therapeutic target for TC, or both.

Hypoxia is an important cause of increased tumor progression, metastasis, and resistance to anticancer drugs and irradiation [18–20]. CA9 is an isoform of the human αCA family of zinc metalloenzymes, which transport CO$_2$ to the extracellular environment to regulate intracellular pH to protect cells from hypoxia and acidosis [18]. CA9 is transcriptionally regulated by hypoxia through the binding of HIF-1 to a hypoxia response element upstream from the transcription initiation site [18].

Of the CA isoforms, only CA9 and CA12 are highly expressed in cancer tissues and therefore may contribute to the acidification of the extracellular milieu [21]. CA9 expression serves as a prognostic factor of patients with the cancers as follows: lung cancer [22], breast cancer [23–25], nasopharyngeal cancer [26], esophageal cancer [27], brain tumors [28], cervical carcinoma [29], and gastric cancer [30]. Nevertheless, the roles of CA9 in TETs are unknown.

The frequency of detection of CA9 varies from 48% to 80% according to tumor site [25, 27, 29]. For example, an analysis of tissue microarrays found that CA9 serves as a diagnostic marker that distinguishes TCs from type B3 thymomas, though the diagnostic specificity and sensitivity of CA9 was not higher compared with those of glucose transporter 1 (GLUT-1) or KIT [15].

Our present study shows that CA9 was expressed in <30% of TETs, although it was expressed in >80% of TCs. Moreover, CA9 expression was significantly associated with shorter RFS. In an effort to identify the function of CA9 in tumor cells, we found that the hypoxia-related molecules CA9 and GLUT-1 were highly expressed in TC samples. Numerous studies focus on the prognostic significance and clinical utility of 2-[$^{18}$F]-fluoro-2-deoxy-D-glucose ($^{18}$F-FDG) PET imaging of TETs [31–34], indicating the potential influence of

| Clinicopathological factors         | Total | CA9(-) | CA9(+) | $P$ value |
|------------------------------------|-------|--------|--------|-----------|
| age, median (range)                |       |        |        |           |
| gender                             |       |        |        |           |
| male                               | 88    | 67     | 21     | 0.30      |
| female                             | 91    | 75     | 16     |           |
| Masaoka Stage                      |       |        |        |           |
| I                                  | 58    | 54     | 4      | $<0.001^*$ |
| II                                 | 85    | 69     | 16     |           |
| III                                | 23    | 14     | 9      |           |
| IVa                                | 4     | 2      | 2      |           |
| IVb                                | 9     | 3      | 6      |           |
| WHO classification                 |       |        |        |           |
| A                                  | 17    | 17     | 0      | $<0.001^{\dagger}$ |
| AB                                 | 37    | 34     | 3      |           |
| B1                                 | 39    | 38     | 1      |           |
| B2                                 | 40    | 34     | 6      |           |
| B3                                 | 25    | 15     | 10     |           |
| Thymic carcinoma                   | 21    | 4      | 17     |           |
| Combined immune diseases           |       |        |        |           |
| Yes                                | 52    | 40     | 12     | 0.61      |
| MG                                 | 47$^\dagger$ | 35 | 12 |           |
| PRCA                               | 4$^\dagger$ | 3 | 1 |           |
| hypogammaglobulinemia              | 2 | 2 | 0 |           |
| No                                 | 127 | 102 | 25 |           |

Abbreviations: MG: Myasthenia gravis, PRCA: Pure red cell aplasia
$^\dagger$one patient had combined MG and PRCA, $^*$stage I–II vs stage III–IV, $^\dagger$type A-B3 vs thymic carcinoma.
hypoxia and glucose metabolism on TETs. Together, our present data revealing the biological and clinical effects of CA9 expression are therefore consistent with the findings of our comprehensive transcriptome sequence analysis that identified CA9 as a highly significant DEG. Moreover, CA9 may play an important role in the aggressive phenotype of TET and may play a similar role in other malignancies [18, 30].

The putative roles of CA9 are as follows: regulation of intracellular pH to control the tumor microenvironment [35]; regulation of tumor growth and survival [36]; destabilization of intercellular adhesion contacts [35]; promotion of tumor migration, invasion and metastasis [37–40]; and resistance to chemotherapy and radiotherapy [41]. Extracellular hypoxia and acidosis may negatively affect drug uptake and radiation damage through the regulation of pH by CA9 [18, 42]. Here we show that inhibition of CA9 expression reduced the proliferation of TC cells, suggesting that inhibition of CA9 exerts an antitumor effect on TC. Moreover, inhibition of CA9 expression enhanced the radiosensitivity of a TC cell line, suggesting that the combination of radiation and a CA9 inhibitor may synergize to more potently inhibit the growth of TC cells. We observed that inhibition of CA9 expression using siRNA sensitized MP57 to radiation in normoxic condition, but not Ty-82. Although we have to confirm the effect using other TC cell lines in detail, inhibition of CA9 expression might have other synergic effect to improve radiosensitivity of TC cells even in normoxic condition. This possibility is consistent with the survival benefits of postoperative radiotherapy (PORT), which is often used to treat patients with TCs and thymoma [43–45]. A CA9 inhibitor might sensitize TC to PORT or other radiotherapies used to treat recurrent lesions, which will likely lead to improved prognosis of patients with TETs.

Although we extracted tumor samples from the central part of non-necrotic tissues and verified the whole tumor histology, we did not include the morphological control for molecular study. We were not able to collect early-stage TC samples, which could lead to sample bias.

| Characteristics                  | Number of patients (Total = 179) | 5-year OS rate | P value* | 5-year RFS rate | P value* |
|----------------------------------|----------------------------------|----------------|----------|----------------|----------|
| age (years)                      |                                  |                |          |                |          |
| ≤57                              | 92                               | 93.2           | 0.440    | 88.1           | 0.361    |
| >57                              | 87                               | 85.5           |          | 77.5           |          |
| gender                           |                                  |                |          |                |          |
| male                             | 88                               | 83.6           | 0.031†   | 73.4           | 0.002†   |
| female                           | 91                               | 95.7           |          | 92.5           |          |
| Masaoka Stage                    |                                  |                |          |                |          |
| I–II                             | 143                              | 94.6           | < 0.001† | 90.2           | < 0.001† |
| III–IV                           | 36                               | 72.0           |          | 56.4           |          |
| WHO classification               |                                  |                |          |                |          |
| A–B1                             | 93                               | 95.1           | 0.003†   | 92.8           | < 0.001† |
| B2–B3                            | 65                               | 90.5           |          | 82.4           |          |
| Thymic carcinoma                 | 21                               | 69.6           |          | 46.6           |          |
| Combined immune diseases         |                                  |                |          |                |          |
| Yes                              | 52                               | 89.3           | 0.724    | 89.7           | 0.609    |
| No                               | 127                              | 89.9           |          | 79.8           |          |
| CA9 expression                   |                                  |                |          |                |          |
| (–)                              | 142                              | 90.5           | 0.194    | 86.7           | 0.005†   |
| (+)                              | 37                               | 88.0           |          | 69.4           |          |

*Log-rank test †P < .05.
Figure 3: Knockdown of CA9 and its influence on the TC cell line Ty-82 (A–E). (A), Influence of hypoxia on HIF1α and CA9 expression. (B, C), RT-qPCR and Western blot analyses of the effects of CA9-specific siRNA1 and siRNA2 on CA9 expression. Knockdown of CA9 and its influence were examined on another TC cell line MP57 (F–H). (F), Western blot analyses showed both HIF1α and CA9 expressions increased under hypoxia, and CA9-specific siRNA1 and siRNA2 inhibited CA9 expression under hypoxia. The reduction in CA9 expression by the siRNAs did not inhibit cell proliferation under normoxia (D: Ty-82, G: MP57), in contrast to hypoxia (E: Ty-82, H: MP57).
In conclusion, our findings indicate that CA9 is a key molecule that shows significantly higher expression in TCs, and contributes to the aggressiveness of TCs. Moreover, CA9 expression may be involved in the proliferation and radiosensitivity of TC cells. We suggest therefore, that CA9 may serve as a therapeutic target for managing patients with TCs.

MATERIALS AND METHODS

Tissue samples and clinicopathological data of patients with TETs

Surgical specimens were obtained from 188 patients with TETs at Gunma University Hospital between 1991 and 2016. The study was conducted in compliance with the Declaration of Helsinki and approved by the Institutional Review Board (IRB Numbers 160116 and 2016-062). All patients provided written informed consent before their registration in the study. Twenty-three surgically resected TETs and four physiologic thymic specimens were used for RNA sequence analysis to screen for highly expressed genes specific for highly malignant TETs. Formalin-fixed, paraffin-embedded sections of tumor tissues collected from 188 patients with TETs were subjected to immunohistochemical analysis (see below). Of them, 179 samples which were not recurrent tumor were used for clinicopathological and survival analyses.

Pathological stages of the patients with TETs were determined according to the Masaoka classification [2] and WHO classifications. Patients’ clinical data were reviewed, and overall survival (OS, days) was defined as the time between the date of tumor resection and date of death from any cause or last follow-up. Recurrence-free survival (RFS) was defined as the time between the date of tumor resection and the date of any recurrence, death from causes other than cancer, or the last follow-up.

Cell line

The human thymic carcinoma cell line Ty-82 was obtained from the Japanese Collection of Research Bioresources (JCRB) [46]. Ty-82 cells were authenticated and certified as uninfected by the JCRB at the time of purchase. We used the cells within 4 months after purchase. Ty-82 cells were cultured in a flask designed only for culturing nonadherent cell lines (Corning, NY, USA). MP57 is a human thymic carcinoma cell line kindly

Figure 4: CA9 knockdown using siRNA sensitized radiation to TC cells. CA9 knockdown did not influence cellular sensitivity to irradiation under normoxia (A), in contrast to hypoxia (B) in Ty-82 cells, while CA9 knockdown influenced radio-sensitivity both under normoxia (C) and hypoxia (D) in MP57 cells.
Whole transcriptome expression analysis (RNA-seq)

Total RNAs were extracted from non-necrotic central regions of 23 surgically resected TETs and four physiologic thymic specimens using a NucleoSpin RNA kit (TaKaRa Bio, Shiga, Japan). Physiologic thymic specimens were collected simultaneously from the surgically resected thymic tissue corresponding to TETs (TH25N, TH37N, TH41N, and TH42N were collected with TH25, TH37, TH41, and TH42, respectively). Fresh human specimens were collected during surgery and stored in RNA later (Thermo Fisher Scientific) at 4 °C overnight. After removal of the RNA later reagent, samples were stored at −80 °C. RNA quality was assessed using an Agilent Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA), and high-quality RNAs (RNA integrity numbers >7.0) were used for RNA-seq.

Total RNA (1 µg) was used to generate sequencing libraries of barcoded fragments using the TruSeq Stranded mRNA Sample Prep Kit (Illumina, San Diego, CA, USA) following the manufacturer’s instructions. Libraries were subjected to paired-end sequencing of 43-bp reads using a NextSeq500 System (Illumina) with a NextSeq500 High Output Kit (Illumina). The reads were aligned to the UCSC reference human genome 19 (hg19) using a Spliced Transcripts Alignment to a Reference (STAR) software v2.3.1 (DNASTAR, Inc. Madison, WI, USA). DEGs were detected using DESeq v1.24.0 (Bioconductor open-development software project). We identified genes expressed at significantly higher levels in TCs compared with thymoma and physiologic thymic specimens (log2 fold-change >4, adjusted P < 0.05).

Immunohistochemical analysis

Immunohistochemistry was performed using formalin-fixed, paraffin-embedded sections of TET tissues as previously described [48]. After reviewing hematoxylin and eosin-stained surgical specimens, the block containing the most extensive tumor component was selected. Sequential 4-µm sections were deparaffinized and immersed in 0.3% hydrogen peroxide in methanol for 30 min to inhibit endogenous peroxidase activity. For antigen retrieval, the slides were heated at 95 °C for 45 min in distilled water with immunosaver. The slides were then incubated overnight with primary rabbit anti-human CA9 antibody (ab15086, diluted 1:1000) (Abcam, Tokyo, Japan) at 4 °C in a humidified chamber. Negative-control slides were incubated without the primary antibodies, and no detectable staining was observed. Finally, the sections were counterstained using Meyer’s hematoxylin, dehydrated, and mounted. We evaluated a peritumoral tissue far from tumor as physiologic thymic specimens.

Epithelial cells with membrane staining of CA9 of any intensity above background were defined as positive. Approximately 1,000 cells were counted on each slide. For type B1 and B2 thymoma which contain a lot of lymphocytes, we counted tumor cells as much as we could. Positive detection rates were assessed according to the percentage of CA9-positive cells per epithelial cells in the samples. The tumors with ≥20% CA9-positive cancer cells were defined as CA9-positive and those with <20% were defined as CA9-negative.

Protein extraction and Western blotting

Total proteins were extracted from Ty-82 cells using PRO-PREP (iNtRON Biotechnology, Kyungki-Do, Korea) and from MP57 cells using lysis buffer [10% Glycerol, 10mM Tris-HCl (pH7.5), 1mM EDTA, 400 mM NaCl, 0.5% NP40, 4 mg/mL aprotonin, PMSF, proteasome inhibitor MG-132 and 1mM DTT], separated using SDS-PAGE (12.5% gels), electrophoretically transferred to membranes that were then incubated overnight at 4 °C with the antibodies against CA9 (ab15086, 1:2000) (Abcam, Tokyo, Japan), HIF1a (CST #3716, 1:1000) (Cell Signaling Technology, MA, USA), β-actin (CST #3700, 1:1000) (Cell Signaling Technology, MA, USA), and Hsc70 (1:4000) (Sigma, St. Louis, MO, USA). After incubation with horseradish peroxidase-conjugated secondary antibodies, immune complexes were detected using the ECL Prime Western blotting Detection System (GE Healthcare, Tokyo, Japan), and the signals were quantified using an Image Quant LAS 4000 (GE Healthcare).

Knockdown analysis of CA9 expression and real-time RT-PCR

CA9-specific small interfering RNAs (siRNA) (ON-TARGET plus Human CA9 siRNAs J-005244-05 [siRNA1] and J-005244-06 [siRNA2]) were purchased from Dharmaco (GE Healthcare, Japan). Ty-82 and MP57 cells in OPTI-MEM were transfected with the siRNA using an electroporator (CUY21EDIT II, BEX, Tokyo, Japan) according to manufacturer’s protocol. Both cells were seeded in 2 mL of RPMI-1640 in microtiter plates and incubated with siRNAs at 37 °C for 24 h before each assay. Transfected cells were incubated for 48 h or 72h. Total RNA was extracted from cells using the RNeasy Plus Mini Kit and QIAshredder (Qiagen, Hilden, Germany), and the quantity of isolated RNA was measured using an ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA).
The RNA was reverse-transcribed using a ReverTra Ace qPCR RT kit according to the manufacturer’s instructions (Toyobo Life Science, Osaka, Japan) in 5 µl of reaction mixture. To quantitatively compare CA9 mRNA levels, qPCR reactions were performed using the KAPA Probe qPCR master mix (Sigma-Aldrich, St. Louis, MO, USA) with a StepOnePlus real-time PCR system (Thermo Fisher Scientific, MA, USA). The sequences of the primer pairs were as follows: CA9 forward, 5′- CCTTTGCC AGAGTTGACGAG -3′; CA9 reverse, 5′-GCAACTGCT CATAGGCCACTGT -3′. Probe #25 was used. GAPDH mRNA was used to normalize RNA inputs (GAPDH, ABI Probe set; VIC).

**In vitro CCK8 assay**

Ty-82 cells (4.0 × 10^3 cells/well), MP57 cells (2.0 × 10^3 cells/well), Ty-82 cells (4.0 × 10^3 cells/well) were plated in 96-well plates in 10% FBS–RPMI-1640 24 h (Ty-82) or 72 h (MP57) after siRNA transfection. To induce hypoxia, cells were incubated in 1% O_2 for 6 h (Ty-82) or 24 h (MP57) and subsequently cultured under normoxia. After 0 h, 24 h, and 48 h from transfection, 10 µL of CCK-8 solution (CCK-8; Dojindo Laboratories) was added to each well for 2 h at 37°C, and absorbance at 450 nm was determined using an xMark Microplate Absorbance Spectrophotometer (Bio Rad, Hercules, CA, USA). Proliferation rates were calculated using the absorbance at each time compared with those of the plates at 0 h.

**Radiosensitivity assay**

Ty-82 cells (4.0 × 10^3 cells/well), MP57 cells (2.0 × 10^3 cells/well) were plated in 96-well plates in 10% FBS–RPMI-1640 for 24 h (Ty-82) or 72 h (MP57) after siRNA transfection, cultured under hypoxia or normoxia for 6 h (Ty-82) or 24 h (MP57) and then irradiated. After the exposure to different doses of radiation, the plates were incubated under normoxia for 48 h (Ty-82 cells) or 96 h (MP57 cells) before calculation of cell viability (absorbance).

**Statistical analysis**

Survival rates were estimated using the Kaplan–Meier method, and differences in survival between subgroups were compared using the log-rank test. The associations between CA9 expression and clinicopathological factors as well as in vitro data were analyzed using the Student t-test, the Chi-square test, and analysis of variance. P values are two-sided, and the level of significance was set to < 0.05. The analyses were performed using SPSS Statistics 20 statistical software (Dr. SPSS II for Windows; standard version 20.0; SPSS Inc., Chicago, IL, USA), and “R” software (version 3.4.1; R Development Core Team 2017, A Language and Environment for Statistical Computing, R Foundation for Statistical Computing, Vienna, Austria; http://www.r-project.org).

**ACKNOWLEDGMENTS**

The authors thank Ikuko Horikoshi for RNA sequence analysis using NGS and RT-qPCR; Dr. Jun-ichi Saito, Dr. Hiro Sato, and Yuka Hirota for performing the irradiation experiments; Dr. Tomohiro Yazawa, Dr. Yoshiaki Takase, Masaki Shinohara, Yurika Iwata, Ryosuke Kanbe, Ayano Kanazawa, Takeshi Araki, Kaori Takeshita, and Harumi Kanai for collecting tumor samples and clinical data as well as RNA extraction; Dr. Motohiro Arai for pathological advice, and Yusuke Goto for preparing tissue sections. We thank Edanz Group (https://www.edanzediting.com/ac) for editing a draft of this manuscript.

**CONFLICTS OF INTEREST**

None has any financial or other relationship that could lead to a conflicts of interest.

**FUNDING**

This work was supported by Grants-in-Aid for Scientific Research (KAKENHI) from the Japan Society for the Promotion of Science (JSPS; Grant Numbers 26830095); by the Promotion Plan for the Platform of Human Resource Development for Cancer, New Paradigms - Establishing Center for Fostering Medical Researchers of the Future Programs by Ministry of Education, Culture, Sports, Science; and by the Technology of Japan, Gunma University Initiative for Advanced Research (GIAR).

**REFERENCES**

1. Masuda M, Okumura M, Doki Y, Endo S, Hirata Y, Kobayashi J, Kuwano H, Motomura N, Nishida H, Saiki Y, Saito A, Shimizu H, Tanaka F, et al; Committee for Scientific Affairs, The Japanese Association for Thoracic Surgery. Thoracic and cardiovascular surgery in Japan during 2014 : Annual report by The Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg. 2016; 64:665–97. https://doi.org/10.1007/s11748-016-0695-3.

2. Masaoka A, Monden Y, Nakahara K, Tanioka T. Follow-up study of thymomas with special reference to their clinical stages. Cancer. 1981; 48:2485–92.

3. Moon JW, Lee KS, Shin MH, Kim S, Woo SY, Lee G, Han J, Shim YM, Choi YS. Thymic epithelial tumors: prognostic determinants among clinical, histopathologic, and computed tomography findings. Ann Thorac Surg. 2015; 99:462–70. https://doi.org/10.1016/j.athoracsur.2014.09.050.

4. Ruffini E, Detterbeck F, Van Raemdonck D, Rocco G, Thomas P, Weder W, Brunelli A, Evangelista A, Venuta F; European Association of Thoracic Surgeons (ESTS) Thymic Working Group. Tumours of the thymus: a cohort study of prognostic factors from the European Society of Thoracic
Surgeons database. Eur J Cardiothorac Surg. 2014; 46:361–8. https://doi.org/10.1093/ejcts/ezt649.

5. Detterbeck FC, Stratton K, Giroux D, Asamura H, Crowley J, Falkson C, Filosso PL, Frazier AA, Giaccone G, Huang J, Kim J, Kondo K, Lucchi M; Staging and Prognostic Factors Committee; Members of the Advisory Boards; Participating Institutions of the Thymic Domain. The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: proposal for an evidence-based stage classification system for the forthcoming (8th) edition of the TNM classification of malignant tumors. J Thorac Oncol. 2014; 9:S65-72. https://doi.org/10.1097/JTO.0000000000000290.

6. Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, Nicholson AG, Groome P, Mitchell A, Bolejack V; International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, Advisory Boards, and Participating Institutions; International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee Advisory Boards and Participating Institutions. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2016; 11:39-51. https://doi.org/10.1016/j.jtho.2015.09.009.

7. Ahmad U, Yao X, Detterbeck F, Huang J, Antoniellci A, Filosso PL, Ruffini E, Travis W, Jones DR, Zhan Y, Lucchi M, Rimmer A. Thymic carcinoma outcomes and prognosis: results of an international analysis. J Thorac Cardiovasc Surg. 2015; 149:95–100, 101.e1–2. https://doi.org/10.1016/j.jtcvs.2014.09.124.

8. Rajan A, Carter CA, Berman A, Cao L, Kelly RJ, Thomas A, Khozin S, Chavez AL, Bergagnini I, Scepura B, Szabo A, Ballatore Z, Caramanti M, Santoni M, Mazzanti P, Cimino S. Thymic neoplasms: an update on the use of chemotherapy and new targeted therapies. A literature review. Cancer Treat Rev. 2014; 40:495–506. https://doi.org/10.1016/j.cancertr.2013.11.003.

9. Berardi R, De Lisa M, Pagliaretta S, Onofri A, Morgese F, Savini A, Ballatore Z, Caramanti M, Santoni M, Mazzanti P, Cimino S. Thymic neoplasms: an update on the use of chemotherapy and new targeted therapies. A literature review. Cancer Treat Rev. 2014; 40:495–506. https://doi.org/10.1016/j.ctrv.2013.11.003.

10. Lamarca A, Moreno V, Felu J. Thymoma and thymic carcinoma in the target therapies era. Cancer Treat Rev. 2013; 39:413–20. https://doi.org/10.1016/j.ctrv.2012.11.005.

11. Girard N, Shen R, Guo T, Zakowski MF, Heguy A, Riely GJ, Huang J, Lau C, Lash AE, Ladanyi M, Viale A, Antonescu CR, Travis WD, et al. Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas. Clin Cancer Res. 2009; 15:6790–9. https://doi.org/10.1158/1078-0432.CCR-09-0644.

12. Suzuki E, Sasaki H, Kawano O, Endo K, Haneda H, Yukiue H, Kobayashi Y, Yano M, Fujii Y. Expression and mutation statuses of epidermal growth factor receptor in thymic epithelial tumors. Jpn J Clin Oncol. 2006; 36:351–6. https://doi.org/10.1093/jjco/hyl028.

13. Yoh K, Nishiwaki Y, Ishii G, Goto K, Kubota K, Ohmatsu H, Niho S, Nagai K, Saijo N. Mutational status of EGFR and KIT in thymoma and thymic carcinoma. Lung Cancer. 2008; 62:316–20. https://doi.org/10.1016/j.lungcan.2008.03.013.

14. Radovich M, Pickering CR, Felau I, Ha G, Zhang H, Jo H, Hoadley KA, Anur P, Zhang J, McClellan M, Bowly R, Matthew T, Danilova L, et al. The Integrated Genomic Landscape of Thymic Epithelial Tumors. Cancer Cell. 2018; 33:244–58. e10. https://doi.org/10.1016/j.ccell.2018.01.003.

15. Kojika M, Ishii G, Yoshida J, Nishimura M, Hishida T, Ota SJ, Murata Y, Nagai K, Ochiai A. Immunohistochemical differential diagnosis between thymic carcinoma and type B3 thymoma: diagnostic utility of hypoxic marker, GLUT-1, in thymic epithelial neoplasms. Mod Pathol. 2009; 22:1341–50. https://doi.org/10.1038/modpathol.2009.105.

16. Toba H, Kondo K, Sadohara Y, Otsuka H, Morimoto M, Kajitura K, Nakagawa Y, Yoshida M, Kawakami Y, Takizawa H, Kenzaki K, Sakiyama S, Bando Y, Tangoku A. 18F-fluorodeoxyglucose positron emission tomography/computed tomography and the relationship between fluorodeoxyglucose uptake and the expression of hypoxia-inducible factor-1alpha, glucose transporter-1 and vascular endothelial growth factor in thymic epithelial tumours. Eur J Cardiothorac Surg. 2013; 44:e105–12. https://doi.org/10.1093/ejcts/ezt263.

17. Kaira K, Endo M, Abe M, Nakagawa K, Ohde Y, Okumura T, Takahashi T, Murakami H, Tsuya A, Nakamura Y, Naito T, Hayashi I, Serizawa M, et al. Biologic correlation of 2-[18F]-fluoro-2-deoxy-D-glucose uptake and the expression of hypoxia-inducible factor-1alpha, glucose transporter-1 and vascular endothelial growth factor in thymic epithelial tumours. J Thorac Cardiovasc Surg. 2014; 15:191–200. https://doi.org/10.1016/j.jtcvs.2014.09.124.

18. Sedlakova O, Svastova E, Takacova M, Pastorek J, Pastorekova S. Carbonic anhydrase IX, a hypoxia-inducible catalytic component of the pH regulating machinery in tumors. Front Physiol. 2014; 4:400. https://doi.org/10.3389/fphys.2013.00400.

19. Meijer TW, Kaanders JH, Span PN, Bussink J. Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy. Clin Cancer Res. 2012; 18:5585–94. https://doi.org/10.1158/1078-0432.CCR-12-0858.

20. Sowa T, Menju T, Chen-Yoshikawa TF, Takahashi K, Nishikawa S, Nakahishi T, Shikuma K, Motoyama H, Hijiya K, Aoyama A, Sato T, Sonobe M, Harada H, Date H. Hypoxia-inducible factor 1 promotes chemoresistance of lung cancer by inducing carbonic anhydrase IX expression. Cancer Med. 2017; 6:288–97. https://doi.org/10.1002/cam4.991.

21. Parkkila S, Parkkila AK, Saarnio J, Kivela J, Karttunen TJ, Kaunisto K, Waheed A, Sly WS, Tureci O, Virtanen I, Rajaniemi H. Expression of the membrane-associated

www.oncotarget.com 1317 Oncotarget
22. Stewart DJ, Nunez MI, Behrens C, Liu D, Lin YH, Lee JJ, Roth J, Heymach J, Swisher SG, Hong WK, Wistuba II. Membrane carbonyl anhydrase IX expression and relapse risk in resected stage I-II non-small-cell lung cancer. J Thorac Oncol. 2014; 9:675–84. https://doi.org/10.1097/JTO.0000000000000148.

23. Ho D, Huang J, Chapman JW, Leitzel K, Ali SM, Shepherd L, Parulekar WR, Ellis CE, Cresceno RJ, Zhu L, Virk S, Nomikos D, Aparicio S, et al. Impact of serum HER2, TIMP-1, and CAIX on outcome for HER2+ metastatic breast cancer patients: CCTG MA.31 (lapatinib vs. trastuzumab). Breast Cancer Res Treat. 2017; 164:571–580. https://doi.org/10.1007/s10549-017-4273-x.

24. Pinheiro C, Sousa B, Albergaria A, Paredes J, Dufloth R, Vieira D, Schmitt F, Baltazar F. GLUT1 and CAIX expression profiles in breast cancer correlate with adverse prognostic factors and MCT1 overexpression. J Histol Histopathol. 2011; 26:1279–86. https://doi.org/10.14670/HH-26.1279.

25. Chia SK, Wykoff CC, Watson PH, Han C, Leek RD, Pastorek J, Gatter KC, Ratcliffe P, Harris AL. Prognostic significance of a novel hypoxia-regulated marker, carbonyl anhydrase IX, in invasive breast carcinoma. J Clin Oncol. 2001; 19:3660–8. https://doi.org/10.1200/JCO.2001.19.16.3660.

26. Chen Y, Li X, Wu S, Xu G, Zhou Y, Gong L, Li Z, Yang D. Expression of HIF-1alpha and CAIX in nasopharyngeal carcinoma and their correlation with patients’ prognosis. Med Oncol. 2014; 31:304. https://doi.org/10.1007/s12032-014-0304-1.

27. Tanaka N, Kato H, Inose T, Kimura H, Faried A, Sohda M, Nakajima M, Fukai Y, Miyazaki T, Masuda N, Fukuchi M, Kuwano H. Expression of carbonyl anhydrase 9, a potential intrinsic marker of hypoxia, is associated with poor prognosis in oesophageal squamous cell carcinoma. Br J Cancer. 2008; 99:1468–75. https://doi.org/10.1038/sj.bjc.6604719.

28. Haapasalo JA, Nordfors KM, Hilvo M, Rantala IJ, Soini Y, Parkkila AK, Pastorekova S, Pastorek J, Parkkila SM, Haapasalo HK. Expression of carbonyl anhydrase IX in astrocytic tumors predicts poor prognosis. Clin Cancer Res. 2006; 12:473–7. https://doi.org/10.1158/1078-0432.CCR-05-0848.

29. Lancaster JA, Harris AL, Davidson SE, Logue JP, Hunter RD, Wycoff CC, Pastorek J, Ratcliffe PJ, Stratford IJ, West CM. Carbonyl anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res. 2001; 61:6394–9.

30. Driessen A, Landuyt W, Pastorekova S, Moons J, Goethals L, Haustermans K, Nafteux P, Penninckx F, Geboes K, Lerut T, Ectors N. Expression of carbonyl anhydrase IX (CA IX), a hypoxia-related protein, rather than vascular-endothelial growth factor (VEGF), a pro-angiogenic factor, correlates with an extremely poor prognosis in esophageal and gastric adenocarcinomas. Ann Surg. 2006; 243:334–40. https://doi.org/10.1097/01.sla.0000201452.09591.f3.

31. Thomas A, Men a E, Kurtdzieł K, Venzon D, Khozin S, Berman AW, Choyke P, Szabo E, Rajan A, Giacccone G. 18F-fluorodeoxyglucose positron emission tomography in the management of patients with thymic epithelial tumors. Clin Cancer Res. 2013; 19:1487–93. https://doi.org/10.1158/1078-0432.CCR-12-2929.

32. Fukumoto K, Taniguchi T, Ishikawa Y, Kagawachi K, Fukui T, Kato K, Matsu K, Yoki K. The utility of [18F]fluorodeoxyglucose positron emission computed tomography in thymic epithelial tumours. Eur J Cardiothorac Surg. 2012; 42:e152-6. https://doi.org/10.1093/ejcts/ezs527.

33. Kaira K, Sunaga N, Ishizuka T, Shimizu K, Yamamoto N. The role of [18F]fluorodeoxyglucose positron emission tomography in thymic epithelial tumors. Cancer Imaging. 2011; 11:195–201.

34. Igai H, Matsuura N, Takumi S, Chang SS, Misaki N, Go T, Ishikawa Y, Yokomise H. Usefulness of [18F]fluorodeoxyglucose positron emission tomography for predicting the World Health Organization malignancy grade of thymic epithelial tumors. Eur J Cardiothorac Surg. 2011; 40:143–5. https://doi.org/10.1016/j.ejcts.2010.09.009.

35. Svastová E, Hulíková A, Rafajlová M, Zat’ovicová M, Gibadulinová A, Casini A, Cecchi A, Scozzafava A, Supuran CT. GLUT1 and CAIX expression profiles in breast cancer correlate with adverse prognosis and decreased invasion of tumor cells. Oncol Rep. 2013; 29:1147–53.

36. Robertson N, Potter C, Harris AL. Role of carbonyl anhydrase IX in human tumor cell growth, survival, and invasion. Cancer Res. 2004; 64:6160–5. https://doi.org/10.1158/0008-5472.CAN-03-2224.

37. Ward C, Meehan J, Mullen P, Supuran C, Dixon JM, Thomas JS, Winum JY, Lambin P, Dubois L, Pavathaneni NK, Jarman EJ, Renshaw L, Um IH, et al. Evaluation of carbonyl anhydrase IX as a therapeutic target for inhibition of breast cancer invasion and metastasis using a series of in vitro breast cancer models. Oncotarget. 2015; 6:24856–70. https://doi.org/10.18632/oncotarget.4498.

38. Radvak P, Repic M, Svastova E, Takacova M, Csaderova L, Strnad H, Pastorek J, Pastorekova S, Kopacek J. Suppression of carbonyl anhydrase IX leads to aberrant focal adhesion and decreased invasion of tumor cells. Oncol Rep. 2013; 29:1147–53. https://doi.org/10.3892/or.2013.2226.

39. Gieling RG, Babur M, Mamnani L, Burrows N, Shepherd L, Parulekar WR, Ellis CE, Cresczo RJ, Zhu L, Ishikawa Y, Yokomise H. Usefulness of [18F]fluorodeoxyglucose positron emission tomography for inhibition of breast cancer invasion and metastasis using a series of in vitro breast cancer models. Oncotarget. 2015; 6:24856–70. https://doi.org/10.18632/oncotarget.4498.
40. Gieling RG, Williams KJ. Carbonic anhydrase IX as a target for metastatic disease. Bioorg Med Chem. 2013; 21:1470–6. https://doi.org/10.1016/j.bmc.2012.09.062.

41. Dubois L, Peeters SG, van Kuijk SJ, Yaromina A, Lieuwes NG, Saraya R, Biemans R, Rami M, Parvathaneni NK, Vullo D, Voojis M, Supuran CT, Winum JY, Lambin P. Targeting carbonic anhydrase IX by nitroimidazole based sulfamides enhances the therapeutic effect of tumor irradiation: a new concept of dual targeting drugs. Radiother Oncol. 2013; 108:523–8. https://doi.org/10.1016/j.radonc.2013.06.018.

42. Wojtkowiak JW, Verduzco D, Schramm KJ, Gillies RJ. Drug resistance and cellular adaptation to tumor acidic pH microenvironment. Mol Pharm. 2011; 8:2032–8. https://doi.org/10.1021/mp200292c.

43. Jackson MW, Palma DA, Camidge DR, Jones BL, Robin TP, Sher DJ, Koshy M, Kavanagh BD, Gaspar LE, Rusthoven CG. The Impact of Postoperative Radiotherapy for Thymoma and Thymic Carcinoma. J Thorac Oncol. 2017; 12:734–44. https://doi.org/10.1016/j.jtho.2017.01.002.

44. Hamaji M, Shah RM, Ali SO, Bettenhausen A, Lee HS, Burt BM. A Meta-Analysis of Postoperative Radiotherapy for Thymic Carcinoma. Ann Thorac Surg. 2017; 103:1668–75. https://doi.org/10.1016/j.athoracsur.2016.12.042.

45. Lim YJ, Song C, Kim JS. Improved survival with postoperative radiotherapy in thymic carcinoma: A propensity-matched analysis of Surveillance, Epidemiology, and End Results (SEER) database. Lung Cancer. 2017; 108:161–7. https://doi.org/10.1016/j.lungcan.2017.03.020.

46. Kuzume T, Kubonishi I, Takeuchi S, Takeuchi T, Iwata J, Sonobe H, Ohtsuki Y, Miyoshi I. Establishment and characterization of a thymic carcinoma cell line (Ty-82) carrying t(15;19)(q15;p13) chromosome abnormality. Int J Cancer. 1992; 50:259–64.

47. Alberobello AT, Wang Y, Beerens FJ, Conforti F, McCutcheon JN, Rao G, Raffeld M, Liu J, Rahhal R, Zhang YW, Giaccone G. PI3K as a Potential Therapeutic Target in Thymic Epithelial Tumors. J Thorac Oncol. 2016; 11:1345–56. https://doi.org/10.1016/j.jtho.2016.04.013.

48. Yokobori T, Bao P, Fukuchi M, Altan B, Ozawa D, Rokudai S, Bai T, Kumakura Y, Honjo H, Hara K, Sakai M, Sohda M, Miyazaki T, et al. Nuclear PROX1 is Associated with Hypoxia-Inducible Factor 1alpha Expression and Cancer Progression in Esophageal Squamous Cell Carcinoma. Ann Surg Oncol. 2015; 22 Suppl 3:S1566–73. https://doi.org/10.1245/s10434-015-4831-6.